Last checked at 7 Apr 2022 07:00
Publication of Notice of Annual General Meeting and Annual Report
Dublin, London | 7 April 2022: Uniphar plc (the "Company" or "Uniphar") wishes to announce that it is today posting to shareholders its Notice of Annual General Meeting ("AGM") for 2022 together with its annual report and accounts for the year ended 31 December 2021 ("Annual Report"). The AGM will be held at 11.00 a.m. on 11 May 2022 at the offices of William Fry LLP, 2 Grand Canal Square, Dublin 2, D02 A342.
Uniphar values the participation of its shareholders at its AGM and encourages all shareholders to take part in the meeting either in person or by voting and raising questions in advance. The Company acknowledges that many shareholders will not be in a position to physically attend the meeting in person and as such has put in place a number of measures to facilitate remote participation by all shareholders as detailed below. In the interests of the health and safety of all attendees we would encourage those intending to attend in person to carry out an antigen test in advance of attending the meeting.
The Notice of Meeting, Form of Proxy, Annual Report and accounts are available to view on the Company's website at www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2022/ and will be available for inspection during normal business hours on any business day from today until the conclusion of the AGM at the registered office of the Company.
Proxy voting can be carried out in advance of the AGM. Details of how to do so are set out in further detail in the Notice of Meeting.
A conference call facility will be provided to allow shareholders to listen live to the business of the AGM. Please note that you will not be able to use this facility to vote, raise points or issues or ask questions. If you wish to listen live to the AGM proceedings, you can register for the conference call and receive participant log-in details at www.uniphar.ie/static/investors/shareholder-centre/agm/agm-2022/. Shareholders availing of this facility should ensure to submit any votes in advance of the meeting as it will not be possible to vote using the conference call facility.
Shareholders are invited to submit questions in writing in advance of the meeting either by email to companysecretary@uniphar.ie or by post to the Company Secretary, Uniphar plc, 4045 Kingswood Road, Citywest Business Park, Co. Dublin, D24 V06K, Ireland. Questions must be received by 11.00 a.m. on 9 May 2022. Shareholders must include their Shareholder Reference Number (as set out on their Form of Proxy) with any question submitted.
The meeting will be held in accordance with prevailing Government COVID-19 related restrictions and public health guidance, if any. As the meeting arrangements could change at short notice any such change will be communicated to shareholders by way of Regulatory Information Service. The Board encourages shareholders to check Regulatory Information Services and the Company's website www.uniphar.ie for any updates in relation to the AGM. Shareholders are also encouraged to keep up to date with, and follow, Government restrictions and public health guidance, if any, as circumstances may change at short notice.
For further details contact:
Uniphar | +353 (0) 1 428 7777 |
|
|
Seamus Egan |
|
Head of Corporate Development & IR | investor.relations@Uniphar.ie |
|
|
Davy |
+353 (0) 1 679 6363 |
(Joint Broker, Nominated Adviser and Euronext Growth Adviser) |
|
|
|
Barry Murphy |
|
Niall Gilchrist Lauren O'Sullivan |
|
|
|
RBC Capital Markets (Joint Broker) | +44 (0) 20 7653 4000 |
|
|
Jonathan Hardy |
|
Jamil Miah |
|
Stifel Nicolaus Europe Limited (Joint Broker) | +44 (0) 20 7710 7600 |
|
|
Matt Blawat |
|
Ben Maddison |
|
Francis North |
|
|
|
Q4 PR | +353 (0) 1 475 1444 or |
(Public Relations Adviser to Uniphar) | +353 87 235 6461 |
Iarla Mongey |
|
About Uniphar plc
Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. The Group is active in Ireland, the UK, the Benelux, the Nordics, Germany, and the US.
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Commercial & Clinical
In Commercial & Clinical, the Group provides outsourced sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers. Active in Ireland, the UK, the Benelux, the Nordics, Germany and the US, the Group is growing with its clients to provide pan-European solutions, with a bespoke offering in the US. Uniphar has built fully integrated digitally enabled customer centric solutions that are supported by our highly experienced and clinically trained teams, leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.
Product Access
In Product Access, the Group is growing two distinct service offerings: 1) "On Demand", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with c. 53% market share in the wholesale/hospital market, supported by a network of 378 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are also utilised for the benefit of Commercial & Clinical and Product Access.